Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 4: 474 - 479

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.04.010

Review

Advances in fluorescence imaging of malignant tumors

  • Wenbo WANG ,
  • Fangrong ZHANG ,
  • Tingwang SHI ,
  • Yunfeng CHEN
Expand
  • 1.Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China
    2.Guangzhou Institute of Technology, Xidian University, Guangzhou 510555, China
CHEN Yunfeng, E-mail: chenyf@sjtu.edu.cn.

Received date: 2022-09-06

  Accepted date: 2023-02-21

  Online published: 2023-04-28

Supported by

National Natural Science Foundation of China(82172455);Medical Engineering Cross Project of Shanghai Jiao Tong University(YG2021ZD22);Biomedical Science and Technology Project of Science and Technology Commission of Shanghai Municipality(22S31900200)

Fold

Abstract

Malignant tumors are common diseases that threaten human health. Early diagnosis and complete resection can significantly improve the prognosis of patients with malignant tumors. At present, the imaging techniques used clinically for malignant tumor detection have problems such as poor sensitivity and temporal-spatial resolution, long scanning time, etc., which cannot achieve early diagnosis and meet the requirements of surgical navigation. As a new imaging technology with excellent imaging characteristics, fluorescence imaging can perform real-time imaging of the structure and function of biological tissues and organs. It can realize the accurate detection of malignant tumors by designing fluorescent probes with high sensitivity, high selectivity and specificity. The sensitivity of fluorescence imaging mainly depends on the fluorophore of the probe, and the selectivity and specificity mainly depend on whether the probe adopts an effective targeting strategy. Studies have shown that near infrared fluorophores with emission wavelengths in the near infrared window, especially those in the near infrared Ⅱ window, have excellent optical properties, which can effectively improve the sensitivity of fluorescence imaging of malignant tumors; at the same time, based on the unique structure and metabolic features of malignant tumors, various targeting strategies have been developed to design "always-on" fluorescent probes and "turn-on" fluorescent probes, which significantly improved the selectivity and specificity of fluorescent imaging of malignant tumors. In this paper, the newly developed near infrared fluorophores and the strategies of fluorescent probes targeting malignant tumors are reviewed.

Key words： fluorescence imaging; malignant tumor; near infrared fluorophore; "always on" fluorescent probe; "turn on" fluorescent probe

Cite this article

Wenbo WANG , Fangrong ZHANG , Tingwang SHI , Yunfeng CHEN . Advances in fluorescence imaging of malignant tumors[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(4) : 474 -479 . DOI: 10.3969/j.issn.1674-8115.2023.04.010

References

1 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 EGLOFF-JURAS C, BEZDETNAYA L, DOLIVET G, et al. NIR fluorescence-guided tumor surgery: new strategies for the use of indocyanine green[J]. Int J Nanomedicine, 2019, 14: 7823-7838.
3 SCHOUW H M, HUISMAN L A, JANSSEN Y F, et al. Targeted optical fluorescence imaging: a meta-narrative review and future perspectives[J]. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4272-4292.
4 WANG S, REN W X, HOU J T, et al. Fluorescence imaging of pathophysiological microenvironments[J]. Chem Soc Rev, 2021, 50(16): 8887-8902.
5 ITO R, KAMIYA M, URANO Y. Molecular probes for fluorescence image-guided cancer surgery[J]. Curr Opin Chem Biol, 2022, 67: 102112.
6 TANG Y F, PEI F, LU X M, et al. Recent advances on activatable NIR-Ⅱ fluorescence probes for biomedical imaging[J]. Adv Optical Mater, 2019, 7(21): 1900917.
7 LI C, GUAN X, ZHANG X, et al. NIR-Ⅱ bioimaging of small molecule fluorophores: from basic research to clinical applications[J]. Biosens Bioelectron, 2022, 216: 114620.
8 LI S J, CHENG D, HE L W, et al. Recent progresses in NIR-Ⅰ/Ⅱfluorescence imaging for surgical navigation[J]. Front Bioeng Biotechnol, 2021, 9: 768698.
9 CHEN Q Y, XIE J W, ZHONG Q, et al. Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2020, 155(4): 300-311.
10 HE K S, HONG X P, CHI C W, et al. Efficacy of near-infrared fluorescence-guided hepatectomy for the detection of colorectal liver metastases: a randomized controlled trial[J]. J Am Coll Surg, 2022, 234(2): 130-137.
11 LI D L, LIU Q, QI Q R, et al. Gold nanoclusters for NIR-Ⅱ fluorescence imaging of bones[J]. Small, 2020, 16(43): e2003851.
12 LI D F, HE S Q, WU Y F, et al. Excretable lanthanide nanoparticle for biomedical imaging and surgical navigation in the second near-infrared window[J]. Adv Sci (Weinh), 2019, 6(23): 1902042.
13 ZHOU H, LI S S, ZENG X D, et al. Tumor-homing peptide-based NIR-Ⅱ probes for targeted spontaneous breast tumor imaging[J]. Chin Chem Lett, 2020, 31(6): 1382-1386.
14 KALYANE D, RAVAL N, MAHESHWARI R, et al. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer[J]. Mater Sci Eng C Mater Biol Appl, 2019, 98: 1252-1276.
15 JOSHI B P, HARDIE J, FARKAS M E. Harnessing biology to deliver therapeutic and imaging entities via cell-based methods[J]. Chemistry, 2018, 24(35): 8717-8726.
16 ON K C, RHO J, YOON H Y, et al. Tumor-targeting glycol chitosan nanoparticles for image-guided surgery of rabbit orthotopic VX2 lung cancer[J]. Pharmaceutics, 2020, 12(7): 621.
17 XU Y L, WU H, HUANG J, et al. Probing and enhancing ligand-mediated active targeting of tumors using sub-5 nm ultrafine iron oxide nanoparticles[J]. Theranostics, 2020, 10(6): 2479-2494.
18 DE JONGH S J, TJALMA J J J, KOLLER M, et al. Back-table fluorescence-guided imaging for circumferential resection margin evaluation using bevacizumab-800CW in patients with locally advanced rectal cancer[J]. J Nucl Med, 2020, 61(5): 655-661.
19 VOSKUIL F J, DE JONGH S J, HOOGHIEMSTRA W T R, et al. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: a quantitative dose-escalation study[J]. Theranostics, 2020, 10(9): 3994-4005.
20 MUSELAERS C H J, STILLEBROER A B, RIJPKEMA M, et al. Optical imaging of renal cell carcinoma with anti-carbonic anhydrase Ⅸ monoclonal antibody girentuximab[J]. J Nucl Med, 2014, 55(6): 1035-1040.
21 ZETTLITZ K A, TSAI W T K, KNOWLES S M, et al. Dual-modality immuno-PET and near-infrared fluorescence imaging of pancreatic cancer using an anti-prostate stem cell antigen cys-diabody[J]. J Nucl Med, 2018, 59(9): 1398-1405.
22 BOOGERD L S F, BOONSTRA M C, PREVOO H A J M, et al. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: preclinical validation[J]. Surg Oncol, 2019, 28: 1-8.
23 AMINI A, SAFDARI Y, TASH SHAMSABADI F. Near-infrared fluorescence imaging of EGFR-overexpressing tumors in the mouse xenograft model using scFv-IRDye800CW and cetuximab-IRDye800CW[J]. Mol Imaging, 2022, 2022: 9589820.
24 DE VALK K S, DEKEN M M, HANDGRAAF H J M, et al. First-in-human assessment of cRGD-ZW800-1, a zwitterionic, integrin-targeted, near-infrared fluorescent peptide in colon carcinoma[J]. Clin Cancer Res, 2020, 26(15): 3990-3998.
25 MO T, LIU X Y, LUO Y Q, et al. Aptamer-based biosensors and application in tumor theranostics[J]. Cancer Sci, 2022, 113(1): 7-16.
26 WANG J, FANG X N, ZHANG C C, et al. Development of aptamer-based molecular tools for rapid intraoperative diagnosis and in vivo imaging of serous ovarian cancer[J]. ACS Appl Mater Interfaces, 2021, 13(14): 16118-16126.
27 ZHU L, ZHONG Y, WU S, et al. Cell membrane camouflaged biomimetic nanoparticles: focusing on tumor theranostics[J]. Mater Today Bio, 2022, 14: 100228.
28 RAO L, HE Z B, MENG Q F, et al. Effective cancer targeting and imaging using macrophage membrane-camouflaged upconversion nanoparticles[J]. J Biomed Mater Res A, 2017, 105(2): 521-530.
29 ZHANG Y, ZHANG G P, ZENG Z L, et al. Activatable molecular probes for fluorescence-guided surgery, endoscopy and tissue biopsy[J]. Chem Soc Rev, 2022, 51(2): 566-593.
30 BOEDTKJER E, PEDERSEN S F. The acidic tumor microenvironment as a driver of cancer[J]. Annu Rev Physiol, 2020, 82: 103-126.
31 ZHAO T, HUANG G, LI Y, et al. A transistor-like pH nanoprobe for tumour detection and image-guided surgery[J]. Nat Biomed Eng, 2016, 1: 0006.
32 WITJES M, VOSKUIL F, STEINKAMP P, et al. Fluorescence guided surgery using the pH-activated micellar tracer ONM-100: first-in-human proof of principle in head and neck squamous cell carcinoma[J]. J Oral Maxillofac Surg, 2019, 77(9): e38.
33 DOU K, HUANG W J, XIANG Y H, et al. Design of activatable NIR-Ⅱ molecular probe for in vivo elucidation of disease-related viscosity variations[J]. Anal Chem, 2020, 92(6): 4177-4181.
34 UNKART J T, CHEN S L, WAPNIR I L, et al. Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase 1 study[J]. Ann Surg Oncol, 2017, 24(11): 3167-3173.
35 SMITH B L, LANAHAN C R, SPECHT M C, et al. Feasibility study of a novel protease-activated fluorescent imaging system for real-time, intraoperative detection of residual breast cancer in breast conserving surgery[J]. Ann Surg Oncol, 2020, 27(6): 1854-1861.
36 CAO J, ZHU B L, ZHENG K F, et al. Recent progress in NIR-Ⅱ contrast agent for biological imaging[J]. Front Bioeng Biotechnol, 2020, 7: 487.
Options
Outlines

/

〈 〉